ADC Therapeutics competes within the fiercely competitive oncology and targeted therapeutics sectors against numerous specialized biotechnology firms and multinational pharmaceutical giants. Primary market competitors include companies developing advanced antibody-drug conjugates and targeted cancer treatments, such as Seagen (Pfizer), ImmunoGen (AbbVie), Gilead Sciences, Daiichi Sankyo, AstraZeneca, Sutro Biopharma, and other innovative clinical-stage oncology developers.